Malaria drug's warnings strengthened by FDA

The FDA updated on Monday the warning on the antimalarial treatment mefloquine hydrochloride, which is sold under brand names such as Mefliam, Mephaquin and Lariam. The drug's label must bear the black box warning because the treatment could cause psychiatric adverse events including depression, paranoia, confusion and anxiety, as well as neurologic side effects including tinnitus, loss of balance and dizziness, the agency said. "FDA has revised the patient Medication Guide dispensed with each prescription and wallet card to include this information and the possibility that the neurologic side effects may persist or become permanent," the agency said in a statement.

View Full Article in:

New York Times (tiered subscription model), The · NBC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC